(Q37968047)

26 August 2017

title

Mouse models for LRRK2 Parkinson's disease (English)

1 reference

26 August 2017

1 reference

Qing Xu

1

1 reference

26 August 2017

Sushila Shenoy

series ordinal

2

1 reference

26 August 2017

Chenjian Li

series ordinal

3

1 reference

26 August 2017

publication date

1 January 2012

1 reference

Parkinsonism and Related Disorders

26 August 2017

published in

1 reference

26 August 2017

volume

18 Suppl 1

1 reference

26 August 2017

page(s)

S186-9

1 reference

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Genealogical studies in LRRK2-associated Parkinson's disease in central Norway

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Subclinical signs in LRRK2 mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

LRRK2 R1398H polymorphism is associated with decreased risk of Parkinson's disease in a Han Chinese population.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Lrrk2 S1647T and BDNF V66M interact with environmental factors to increase risk of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Ageing and Parkinson's disease: substantia nigra regional selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970058-X

7 January 2021

10.1016/S1353-8020(11)70058-X

Identifiers

DOI

1 reference

26 August 2017

1 reference